Onco Wiki / Indicación

Carcinoma paratiroideo · línea 2 · Pembrolizumab en monoterapia

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.

Fuente YAML: registro completo

Notas

STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode- exempted draft content). Reuses REG-PEMBROLIZUMAB-MONO (cross-disease generic pembrolizumab-monotherapy regimen already in the KB) and DRUG-PEMBROLIZUMAB rather than creating a duplicate regimen. No parathyroid-carcinoma-specific pembrolizumab trial exists; evidence is extrapolated from the tissue-agnostic MSI-H/dMMR (KEYNOTE-158/164) and TMB-high FDA approvals for solid tumors generally — see DRUG-PEMBROLIZUMAB.regulatory_status.fda.indications_brief and BIO-TMB-HIGH.interpretation_notes (both already in the KB) for that basket-trial context. `sources` cite the two disease-level NCCN guidelines already attached to DIS-PARATHYROID-CARCINOMA as `position: context` (cross-cutting biomarker-driven-therapy principle) rather than `supports`, because neither guideline directly addresses parathyroid carcinoma pembrolizumab use — no new Source stub was authored for KEYNOTE-158 because it is not explicitly named in the Disease narrative supplied for this task. Given the extreme rarity of parathyroid carcinoma, disease-specific prospective trial data is unlikely to ever exist — this Indication documents the best available (tiss...

Utilizado por

Algoritmos

• ALGO-PARATHYROID-CARCINOMA-1L - ALGO-PARATHYROID-CARCINOMA-1L

Enfermedad

• DIS-PARATHYROID-CARCINOMA - Carcinoma paratiroideo

Indicación

• IND-PARATHYROID-CARCINOMA-2L-CINACALCET - IND-PARATHYROID-CARCINOMA-2L-CINACALCET